EP0752815A1 - Method of killing microorganisms - Google Patents

Method of killing microorganisms

Info

Publication number
EP0752815A1
EP0752815A1 EP95928872A EP95928872A EP0752815A1 EP 0752815 A1 EP0752815 A1 EP 0752815A1 EP 95928872 A EP95928872 A EP 95928872A EP 95928872 A EP95928872 A EP 95928872A EP 0752815 A1 EP0752815 A1 EP 0752815A1
Authority
EP
European Patent Office
Prior art keywords
glucose
hours
glucose oxidase
resulting mixture
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95928872A
Other languages
German (de)
French (fr)
Inventor
David Wilson Ashworth
Walter Graham Guthrie
David Vincent Roper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP0752815A1 publication Critical patent/EP0752815A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins

Definitions

  • the present invention relates to a method of killing microorganisms such as bacteria, protozoa, fungi and viruses and to a packaged chemical composition suitable for use in such a method.
  • the present invention provides a method of killing microorganisms by mixing effective amounts of D-glucose and glucose oxidase, incubating the resulting mixture at a temperature of from -10 to 50°C and at a pH of from 1 to 8 for a period of at least about 30 minutes and then applying the incubated mixture to the microorganisms to be killed.
  • the method of the invention provides improved speed of kill.
  • the resulting mixture is incubated for at least 1 hour, preferably at least 2 hours, more preferably at least 4 hours.
  • the inventors have found that the fast-kill activity increases rapidly on incubation from 30 minutes to 48 hours.
  • a favoured incubation period is 12 to 48 hours .
  • a particularly favoured incubation period is 24 hours, as the mixture can be made up a day in advance and the incubation step carried out during transport to an end user.
  • the incubated mixture of the invention has been found to retain its fast-kill properties for at least a 2 year test period.
  • the concentration of glucose oxidase in the resulting mixture is at least 25 U/kg, suitably at least 150 U/kg.
  • the resulting mixture comprises iodide anions and/or thiocyanate anions.
  • the resulting mixture comprises both iodide anions and thiocyanate anions, suitably in a weight : weight ratio within the range 0.1:1 to 50:1 and suitably to a combined anion weight concentration of at least 5 mg/kg, preferably at least 10 mg/kg.
  • Iodide and thiocyanate anions are generally included in the compositions according to the invention in the form of salts.
  • Suitable iodide salts include alkali metal salts such as potassium iodide and sodium iodide and mixtures thereof.
  • Suitable thiocyanate salts include, for example, potassium, sodium, ammonium, ferric and cuprous salts of thiocyanate and mixtures thereof .
  • the weight concentration of iodide anions is at least 5 mg/kg and the weight concentration of thiocyanate anions is at least 2 mg/kg.
  • the weigh :weight ratio of iodide:thiocyanate anions is preferably in the range 0.2:1 to 20:1, more preferably
  • Ail units (U) of enzyme activity referred to herein relate to International Units of activity defined as the amount of enzyme required to catalyse the transformation of 1.0 micromole of substrate per minute at 25°C under optimal conditions. All concentrations referred to herein relate to amounts per kilogram of the total composition.
  • the method may be used to kill most if not all types of microorganisms, for example gram negative bacteria such as Escherichia coli and Pseudomonas aeruqinosa, gram positive bacteria such as Staphylococcus aureus and Propionibacterium acnes, moulds such as Aspergillus niqer and Penicillium funiculosum, yeasts such as Candida albicans, Saccharomyces cerevisiae and Pityrosporum ovale, dermatophytic fungi such as Trichophvton rubrum, microalgae such as Chlorella spp. and Spyrocryra spp. and viruses such as Herpes virus and Picornavirus .
  • gram negative bacteria such as Escherichia coli and Pseudomonas aeruqinosa
  • gram positive bacteria such as Staphylococcus aureus and Propionibacterium acnes
  • moulds such as As
  • the oxidoreductase enzyme glucose oxidase, catalyses the production of H2O2 by oxidation of D- glucose in the presence of water and oxygen. It is classified as E.C.I.1.3.4. (IUPAC) and is defined herein in International Units (amount of enzyme required to catalyze the oxidation of 1.0 micromole ⁇ -D-glucose per minute at pH 7.0 and 25°C) .
  • Glucose oxidase is available commercially from a number of sources, for example from Sturge-ABM under the trade designations "Glucox P200" (2000 U/ml) and "Glucox PS" (75 U/mg) .
  • Glucose oxidase concentrations in excess of 150 U/kg provide excellent protection against bacterial, mould and yeasc growth.
  • the oxidisable substrate for glucose oxidase is generally included at a con- centraticn (in the resulting mixture, before incubation) of at least 0.2 g/kg, preferably a least 0.5 g/kg, preferably at least 1 g/kg, and more particularly at least 2 g/kg.
  • D-glucose may be provided per se or may be formed in situ from suitable precursors, for example, as a result of the breakdown of an oligomer or polymer containing D-glucose.
  • suitable precursors such as sucrose or starch may be used alone or in admixture with D-glucose and may advantageously support more sustained anti-microbial activity than obtained with D- glucose alone.
  • lactoperoxidase a peroxidase enzyme
  • lactoperoxidase is classified as E.C.I.17.1.7 (IUPAC) and is defined herein in International Units (amount of enzyme required to catalyse the reduction of 1.0 micromole H2O2 per minute at pH 7.0 and 25°C) .
  • Lactoperoxidase is available commercially from a number of sources, for example from DMV (De Melkindustrie Veghel bv) (275 U/mg) .
  • compositions according to the invention which further comprise lactoperoxidase exhibit effective killing activity against the organisms listed above.
  • the method of the invention may, if desired, incorporate further agents which may supplement or enhance the anti-microbial activity thereof, for example other enzymes such as lactoferrin or salts such as calcium chloride.
  • Anti-microbial activity may be enhanced by the addition of agents having antioxidant activity.
  • Typical antioxidants include, for example, butylated hydroxyanisole, butylated hydroxytoluene, ⁇ -tocopherol and esters thereof, ascorbic acid, salts and esters thereof, gallic acid, salts and esters thereof e.g.
  • antioxidants are selected from butylated hydroxyanisole, butylated hydroxytoluene, ⁇ -tocopherol and esters thereof and ascorbic acid, salts and esters thereof, preferably in a weight concentration of at least 1 mg/kg, more preferably at least 50 mg/kg.
  • the use of ⁇ -tocopherol and esters thereof as "natural" antioxidants is particularly preferred.
  • apparatus in the form of a packaged chemical composition for use in the method defined above, said apparatus comprising:
  • the first reservoir further comprises a source of thiocyanate and/or iodide anions .
  • the second reservoir further comprises a source of lactoperoxidase.
  • the effective concentrations of D- glucose, glucose oxidase, lactoperoxidase and thiocyanate and iodide are such as to provide a biocidal mixture having the following composition on mixing (but before incubation) : (i) 10 to 500 mg/kg iodide anions; (ii) 5 to 200 mg/kg thiocyanate anions; (iii)0.2 to 100 g/kg D-glucose; and (iv) 150 to 20000 U/kg glucose oxidase;
  • weight : weight ratio of iodide : thiocyanate anions is 0.2:1 to 20:1 and the combined anion weight concentration is at least 25 mg/kg, in combination with a suitable carrier or excipient.
  • Concentrated biphasic compositions in packaged and substantially non- reacting form which may be stored for prolonged periods prior to use.
  • Concentrated compositions according to the invention will maintain physical separation of the glucose oxidase and its substrate, namely D-glucose, such that H2O2 production is substantially prevented during storage.
  • prior to storage concentrated compositions may contain a low level of at least one such substrate sufficient to support an initial reaction but insufficient to sustain activity under the desired storage conditions.
  • the initial reaction may advantageously provide adequate self-preservation of the concentrated compositions according to the invention.
  • Self-preservation is of particular benefit in aqueous concentrates according to the invention which may otherwise re ⁇ aries the use of conventional chemical preservatives to avoid microbial spoilage during storage.
  • the substantially non-reacting concentrated compositions according to the invention are intended to be mixed or diluted and activated immediately prior to use by bringing the glucose oxidase and substrates thereof into intimate admixture to produce compositions having the desired anti-microbial properties .
  • the concentrated compositions according to the invention optionally further comprise suitable carriers and/or excipients.
  • the compositions may incorporate at least one buffering agent to minimise the fall of pH which may otherwise occur after activation of the . concentrated composition.
  • the concentrated compositions may be provided in the form of packs containing one or more discrete units of an appropriate weight or volume for batch or unit dosing.
  • compositions according to the invention may comprise substantially anhydrous mixtures of each of the essential components mentioned hereinbefore, optionally combined with suitable non- aqueous carriers or excipients.
  • Concentrated water-containing compositions may be packaged and maintained prior to use. They may be in the form of, for example, solutions, suspensions, pastes or gels.
  • compositions useful in the present invention may take the form of two or more powders, liquids, pastes or gels which prevent the glucose oxidase and D-glucose from reacting until the two are combined prior to use.
  • the glucose and D-glucose might be formulated as dry granules to be activated by addition of liquid prior to use, allowing the reagents to react. Examples of such products include :
  • deodorants e.g. for topical administration in the form of roll-on or stick formulations
  • antibacterial skin washes e.g. in the form of lotions
  • anti-acne preparations e.g. in the form of lotions or creams
  • anti-athlete's foot preparations e.g. in the form of lotions
  • anti-dandruff preparations e.g. in the form of shampoos or lotions
  • dental preparations e.g. mouth washes suitable for general oral hygiene and in particular having anti- plaque properties, and dentifrices such as toothpastes, toothpowders, chewing gums and lozenges
  • impregnated materials e.g.
  • wound dressings sutures and dental floss
  • pharmaceuticals e.g. wound irrigants and burn treatments, anti-diarrhoeal agents and medicaments suitable for the treatment of infections such as Candida and Tinea infections
  • ophthalmic preparations e.g. eye washes and solutions for rinsing and/or sterilising contact lenses
  • sterilants e.g. for baby bottles and surgical or dental instruments.
  • sterilants for use in healthcare/manufacturing environments to decontaminate for example surgical instruments or food processing equipment; and
  • the incubated mixture is provided as a concentrate for dilution to produce a solution for killing microorganisms.
  • the incubation step to activate the mixture for fast-kill activity is carried out during manufacture and/or distribution to an end user.
  • a range of oral hygiene preparations may be envisaged which incorporate the anti-microbial compositions of the invention into conventional dental preparations such as mouthwashes, gargles and dentifrices as an anti-plaque agent and/or as a general antiseptic agent, for example in denture cleansing tablets or solutions.
  • the oral hygiene compositions of the present invention may, if desired, contain one or more active ingredients conventionally used in the art.
  • anti-plaque agents such as bromochlorophene, triclosan, cetylpyridinium chloride and chlorhexidine salts
  • fluoride ion sources such as sodium fluoride, sodium monofluorophosphate and amine fluorides
  • anti-tartar agents such as zinc salts, preferably zinc citrate, and water soluble pyrophosphate salts, preferably alkali metal pyrophosphates
  • agents which reduce tooth sensitivity including potassium salts such as potassium nitrate and potassium chloride and strontium salts such as strontium chloride and strontium acetate.
  • compositions and methods of the invention are suitable for a whole host of anti-microbial applications in areas such as agriculture, horticulture, veterinary medicine, and aquaculture, such as trout farming.
  • Phase A Phase A
  • Both phases were adjusted to between pH 5.5 and 6.5 with buffer solutions.
  • a test solution was prepared by mixing Phases A and
  • the inoculated solution was incubated at room temperature. Samples were taken at regular intervals (viz at 0, 5, 10, 15, 30 and 60 minutes after mixing) and subjected to serial dilution and agar plating in known manner (normal aseptic technique being used throughout) to determine the numbers of any surviving organisms .
  • Comparative Test H The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Aspergillus niger rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 7. Comparative Test H
  • Both phases were adjusted to between pH 5.5 and 6.5 with buffer solutions.
  • Test solutions were prepared by mixing Phases A and
  • test solutions were then stored at room temperature for 48 hours.
  • the inoculated solution was incubated at room temperature for 15 minutes serially diluted and agar plated to determine the numbers of any surviving organisms.
  • pH can be chosen so as to kill a particular micro-organism selectively. For example, at pH 8 only E.coli is killed. Broad spectrum anti-microbial activity is obtained when the pH is around 4 in the above tests .
  • a biphasic glycol paint is prepared to the following composition:
  • Lactoperoxidase 275U (lOppm)
  • Component A Using a suitably designed dispenser 1 part of Component A is combined with 1 part of Component B and allowed to stand for the required activation time. After this period the mixed components can be applied to control two strains of inter alia Staphylococcus aureus and also Propionibacter acnes, Candida albicans, Trichoderma rubrum, Trichoderma mentagrophytes and Trichoderma interdigitale.
  • Staphylococcus aureus and also Propionibacter acnes, Candida albicans, Trichoderma rubrum, Trichoderma mentagrophytes and Trichoderma interdigitale.
  • Propionibacter acnes Candida albicans
  • Trichoderma rubrum Trichoderma rubrum
  • Trichoderma mentagrophytes Trichoderma interdigitale
  • a biphasic roll-on deodorant is prepared to the following composition:
  • Glucose oxidase (available under the Trade Designation "Glucox P200") 260U
  • a biphasic antibacterial anti-dandruff shampoo is prepared to the following composition:
  • Zinc sulphate 0.125g Mixture of diethanolamides (available under the Trade Designation “Empilan CDE”) 6.25g Stearic acid toilet 1.25g Mixture of mono and distearates (available under the Trade Designation “Empilan EGMS”) 3.75g
  • Glucose oxidase (available under the Trade Designation "Glucox P200") 280U (37.5ppm)
  • the components are pre-activated by incubation during manufacture and distribution.
  • the concentration is then diluted 1 part in 100 parts of water to yield a steriling solution with fast-kill activity.
  • the concentrated formulation is advantageous because the weight of product is greatly reduced compared to the liquid solution, making the concentrated product relatively cheap to distribute.
  • the concentrate formulation is also convenient for the end user because it is easier to transport and takes up less storage space than the equivalent liquid solution.
  • Sterilant solution eg for contact lenses
  • a biphasic sterilant solution is prepared to the following composition:
  • Lactoperoxidase 275U (lOppm)
  • Component A Using a suitably designed dispenser 1 part of Component A is combined with 1 part of Component B and allowed to stand for the required activation time. After this period the mixed components can be applied to give effective control of Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Streptococcus mutans, Enterobacter cloacae and Candida albicans.
  • Figure 1 shows a side section view of a packaged chemical composition according to the present invention, along the line I-I of Figure 2;
  • Figure 2 shows a plan section view of the packaged chemical composition of Figure 1 along the line II- II of Figure 1.
  • the packaged chemical composition comprises a first reservoir 2 and a second reservoir 3.
  • the reservoirs are of approximately equal size and are generally tubular in shape.
  • the reservoir walls 4,5 are made from resilient polyethylene but it will be appreciated that other resilient materials, such as polyvinylchloride (PVC) or polyethyleneterephthalate (PET) may also be used if desired.
  • PVC polyvinylchloride
  • PET polyethyleneterephthalate
  • the walls are strong enough to avoid the risk of breakage but flexible enough to permit "squeezing" of the contents in use.
  • One of the reservoirs, 2, houses Component A from Example 1 above and the other reservoir, 3, houses Component B therefrom.
  • the reservoirs 2,3 are substantially sealed so that no leakage of contents can occur from one to the other. For convenience they are welded together at one point by a polythene web 6 which is continuous with the reservoir walls 4,5.
  • the walls of the reservoirs are independently deformable such that it is possible to deform one reservoir, for example by "squeezing", without deforming the other, if desired.
  • the lower end of the reservoirs provide a base 7 to allow the packaging to be rested in an upright position.
  • the upper ends of the reservoirs 2,3 are constricted to form a neck 8 which is blocked by a neck-piece 9 made of stiff non-resilient polyethylene.
  • the neck 8 and neck ⁇ piece 9 support a bulbous incubation chamber 10.
  • the incubation chamber 10 is constricted at its upper end to provide a second neck 11 which is threaded in the manner of a screw-top bottle neck to connect with a screw-cap 12 which may be used to close off the packaging when not in use.
  • Polythene tubes 13,14 extend substantially from the bases of the two reservoirs 2,3 respectively, through holes in the neck-piece 9, with which they form an interference fit, to the base of the incubation chamber 10.
  • the tubes 13,14 are narrow enough to prevent significant leakage of the contents of the reservoirs 2,3 into the incubation chamber 10 during normal storage. Such leakage as may occur is contained by the cap 12. However, when the cap 12 is removed and one or both of the reservoir walls is deformed, for example by "squeezing", a portion of the reservoir contents is forced up the tube 13 or 14 by the pressure created and into the incubation chamber 10.
  • controlled mixing of the reservoir contents is achieved by squeezing each of the reservoirs in turn and/or simultaneously by roughly equal amounts to introduce equal quantities of the reservoir solutions into the incubation chamber 10.
  • Indicia 15 are provided on the walls of the incubation chamber 10 to assist in measuring the quanitities to be mixed.
  • the walls of the incubation chamber are made from transport/translucent polyethylene to assist in the measuring process but this is, not essential and it will be appreciated that opaque plastics materials may be used if desired.
  • the cap 12 may then be replaced and the apparatus 1 may be shaken gently to complete the mixing process. The resulting mixture is left to incubate for the desired period, typically from 5 to 10 minutes.
  • the cap 12 After incubation the cap 12 is removed and the incubated anti-microbial mixture is used in the desired manner, by application to the feet or other areas affected by so-called "athlete's foot".
  • the packaging could house any of the other Examples given above and/or numerous variants thereof.
  • the reservoirs may be made of correspondingly unequal size and corresponding modifications may be made to the other parts of the apparatus as appropriate.
  • the reservoir housing component A may be squeezed four times as often as the reservoir housing component B (as in Example 3 above) , until the desired quantity of mixture has been generated in the incubation chamber 10.
  • the indicia 15 may be used to measure the required proportions.
  • Instructions for mixing the components in the appropriate proportions will normally be supplied with the apparatus, preferably by printing onto the packaging itself.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Microbiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Cosmetics (AREA)

Abstract

A method of killing microorganisms comprises the steps of mixing effective amounts of D-glucose and glucose oxidase, incubating the resulting mixture at a temperature of from -10 to 50 °C and at a pH of from 1 to 8 for a period of at least about 30 minutes and then applying the incubated mixture to the microorganisms.

Description

METHOD OF KILLING MICROORGANISMS
The present invention relates to a method of killing microorganisms such as bacteria, protozoa, fungi and viruses and to a packaged chemical composition suitable for use in such a method.
International Patent Publication No. O91/11105 (The Boots Company PLC) discloses anti-microbial compositions comprising iodide anions and thiocyanate anions in a weight : weight ratio of from 0.1:1 to 50:1 and having a combined anion weight concentration of at least 5 g/kg, D-glucose in a weight concentration of at least 0.2 g/kg and an effective amount of the oxidoreductase enzyme glucose oxidase.
The present invention provides a method of killing microorganisms by mixing effective amounts of D-glucose and glucose oxidase, incubating the resulting mixture at a temperature of from -10 to 50°C and at a pH of from 1 to 8 for a period of at least about 30 minutes and then applying the incubated mixture to the microorganisms to be killed. Remarkably, the method of the invention provides improved speed of kill.
Preferably, the resulting mixture is incubated for at least 1 hour, preferably at least 2 hours, more preferably at least 4 hours. The inventors have found that the fast-kill activity increases rapidly on incubation from 30 minutes to 48 hours.
A favoured incubation period is 12 to 48 hours . A particularly favoured incubation period is 24 hours, as the mixture can be made up a day in advance and the incubation step carried out during transport to an end user. The incubated mixture of the invention has been found to retain its fast-kill properties for at least a 2 year test period.
Preferably, the concentration of glucose oxidase in the resulting mixture is at least 25 U/kg, suitably at least 150 U/kg.
Preferably, the resulting mixture comprises iodide anions and/or thiocyanate anions.
Suitably, the resulting mixture comprises both iodide anions and thiocyanate anions, suitably in a weight : weight ratio within the range 0.1:1 to 50:1 and suitably to a combined anion weight concentration of at least 5 mg/kg, preferably at least 10 mg/kg.
Iodide and thiocyanate anions are generally included in the compositions according to the invention in the form of salts. Suitable iodide salts include alkali metal salts such as potassium iodide and sodium iodide and mixtures thereof. Suitable thiocyanate salts include, for example, potassium, sodium, ammonium, ferric and cuprous salts of thiocyanate and mixtures thereof . Preferably the weight concentration of iodide anions is at least 5 mg/kg and the weight concentration of thiocyanate anions is at least 2 mg/kg. The weigh :weight ratio of iodide:thiocyanate anions is preferably in the range 0.2:1 to 20:1, more preferably
0.5:1 to 15:1, particularly 1:1 to 5:1.
Ail units (U) of enzyme activity referred to herein relate to International Units of activity defined as the amount of enzyme required to catalyse the transformation of 1.0 micromole of substrate per minute at 25°C under optimal conditions. All concentrations referred to herein relate to amounts per kilogram of the total composition.
The method may be used to kill most if not all types of microorganisms, for example gram negative bacteria such as Escherichia coli and Pseudomonas aeruqinosa, gram positive bacteria such as Staphylococcus aureus and Propionibacterium acnes, moulds such as Aspergillus niqer and Penicillium funiculosum, yeasts such as Candida albicans, Saccharomyces cerevisiae and Pityrosporum ovale, dermatophytic fungi such as Trichophvton rubrum, microalgae such as Chlorella spp. and Spyrocryra spp. and viruses such as Herpes virus and Picornavirus .
The oxidoreductase enzyme, glucose oxidase, catalyses the production of H2O2 by oxidation of D- glucose in the presence of water and oxygen. It is classified as E.C.I.1.3.4. (IUPAC) and is defined herein in International Units (amount of enzyme required to catalyze the oxidation of 1.0 micromole β-D-glucose per minute at pH 7.0 and 25°C) . Glucose oxidase is available commercially from a number of sources, for example from Sturge-ABM under the trade designations "Glucox P200" (2000 U/ml) and "Glucox PS" (75 U/mg) . Glucose oxidase concentrations in excess of 150 U/kg provide excellent protection against bacterial, mould and yeasc growth.
The oxidisable substrate for glucose oxidase, namely D-glucose, is generally included at a con- centraticn (in the resulting mixture, before incubation) of at least 0.2 g/kg, preferably a least 0.5 g/kg, preferably at least 1 g/kg, and more particularly at least 2 g/kg. It will be appreciated by those skilled in the art that D-glucose may be provided per se or may be formed in situ from suitable precursors, for example, as a result of the breakdown of an oligomer or polymer containing D-glucose. Suitable precursors such as sucrose or starch may be used alone or in admixture with D-glucose and may advantageously support more sustained anti-microbial activity than obtained with D- glucose alone.
The efficiency of iodide and thiocyanate anion oxidation in the presence of H2O2 may be enhanced by the addition of small amounts of a peroxidase enzyme such as lactoperoxidase, preferably at least 100 U/kg lactoperoxidase. Lactoperoxidase is classified as E.C.I.17.1.7 (IUPAC) and is defined herein in International Units (amount of enzyme required to catalyse the reduction of 1.0 micromole H2O2 per minute at pH 7.0 and 25°C) . Lactoperoxidase is available commercially from a number of sources, for example from DMV (De Melkindustrie Veghel bv) (275 U/mg) . It may be supplied, for example, in the form of a freeze-dried powder or in an aqueous salt solution e.g. 1.8% NaCl or 12% NaCl. The compositions according to the invention which further comprise lactoperoxidase exhibit effective killing activity against the organisms listed above.
The method of the invention may, if desired, incorporate further agents which may supplement or enhance the anti-microbial activity thereof, for example other enzymes such as lactoferrin or salts such as calcium chloride. Anti-microbial activity may be enhanced by the addition of agents having antioxidant activity. Typical antioxidants include, for example, butylated hydroxyanisole, butylated hydroxytoluene, α-tocopherol and esters thereof, ascorbic acid, salts and esters thereof, gallic acid, salts and esters thereof e.g. propyl gallate, σuinones such as 2,5- ditertiary butylhydroquinone, propolis, flavenoi - containing materials such as quercetin, sulphur- containing materials such as dilauryl-3 , 3- thiodipropionate and distearyl-3, 3-thiodipropionate, and mixtures thereof. Preferred antioxidants are selected from butylated hydroxyanisole, butylated hydroxytoluene, α-tocopherol and esters thereof and ascorbic acid, salts and esters thereof, preferably in a weight concentration of at least 1 mg/kg, more preferably at least 50 mg/kg. The use of α-tocopherol and esters thereof as "natural" antioxidants is particularly preferred.
There is also provided apparatus in the form of a packaged chemical composition for use in the method defined above, said apparatus comprising:
a) a first reservoir comprising a source of D-glucose; b) a second reservoir comprising a source of glucose oxidase; c) an incubation chamber connected to said first and second reservoirs; and d) means for introducing controlled quantities of said D-glucose and glucose oxidase into said incubation chamber to prepare and incubate a biocidal mixture of glucose and glucose oxidase ready for use.
Preferably, the first reservoir further comprises a source of thiocyanate and/or iodide anions .
Preferably, the second reservoir further comprises a source of lactoperoxidase.
Suitably, the effective concentrations of D- glucose, glucose oxidase, lactoperoxidase and thiocyanate and iodide are such as to provide a biocidal mixture having the following composition on mixing (but before incubation) : (i) 10 to 500 mg/kg iodide anions; (ii) 5 to 200 mg/kg thiocyanate anions; (iii)0.2 to 100 g/kg D-glucose; and (iv) 150 to 20000 U/kg glucose oxidase;
wherein the weight : weight ratio of iodide : thiocyanate anions is 0.2:1 to 20:1 and the combined anion weight concentration is at least 25 mg/kg, in combination with a suitable carrier or excipient.
One aspect of the invention provides concentrated biphasic compositions in packaged and substantially non- reacting form which may be stored for prolonged periods prior to use. Concentrated compositions according to the invention will maintain physical separation of the glucose oxidase and its substrate, namely D-glucose, such that H2O2 production is substantially prevented during storage. However, it will be understood that prior to storage concentrated compositions may contain a low level of at least one such substrate sufficient to support an initial reaction but insufficient to sustain activity under the desired storage conditions. The initial reaction may advantageously provide adequate self-preservation of the concentrated compositions according to the invention. Self-preservation is of particular benefit in aqueous concentrates according to the invention which may otherwise reσuire the use of conventional chemical preservatives to avoid microbial spoilage during storage. The substantially non-reacting concentrated compositions according to the invention are intended to be mixed or diluted and activated immediately prior to use by bringing the glucose oxidase and substrates thereof into intimate admixture to produce compositions having the desired anti-microbial properties . The concentrated compositions according to the invention optionally further comprise suitable carriers and/or excipients. Advantageously the compositions may incorporate at least one buffering agent to minimise the fall of pH which may otherwise occur after activation of the . concentrated composition. The concentrated compositions may be provided in the form of packs containing one or more discrete units of an appropriate weight or volume for batch or unit dosing.
Concentrated compositions according to the invention may comprise substantially anhydrous mixtures of each of the essential components mentioned hereinbefore, optionally combined with suitable non- aqueous carriers or excipients.
Concentrated water-containing compositions, optionally combined with suitable carriers or excipients, may be packaged and maintained prior to use. They may be in the form of, for example, solutions, suspensions, pastes or gels.
Compositions useful in the present invention may take the form of two or more powders, liquids, pastes or gels which prevent the glucose oxidase and D-glucose from reacting until the two are combined prior to use. For example, the glucose and D-glucose might be formulated as dry granules to be activated by addition of liquid prior to use, allowing the reagents to react. Examples of such products include :
a) deodorants e.g. for topical administration in the form of roll-on or stick formulations; b) antibacterial skin washes e.g. in the form of lotions; c) anti-acne preparations e.g. in the form of lotions or creams; d) anti-athlete's foot preparations e.g. in the form of lotions; e) anti-dandruff preparations e.g. in the form of shampoos or lotions; f) dental preparations e.g. mouth washes suitable for general oral hygiene and in particular having anti- plaque properties, and dentifrices such as toothpastes, toothpowders, chewing gums and lozenges; g) impregnated materials e.g. wound dressings, sutures and dental floss; h) pharmaceuticals e.g. wound irrigants and burn treatments, anti-diarrhoeal agents and medicaments suitable for the treatment of infections such as Candida and Tinea infections; i) ophthalmic preparations e.g. eye washes and solutions for rinsing and/or sterilising contact lenses; j) sterilants e.g. for baby bottles and surgical or dental instruments. k) sterilants for use in healthcare/manufacturing environments to decontaminate for example surgical instruments or food processing equipment; and
1) surface cleaning agents for use in food preparation/handling or healthcare environments to effectively decontaminate working surfaces.
In another aspect, it is preferred that the incubated mixture is provided as a concentrate for dilution to produce a solution for killing microorganisms. In this aspect, the incubation step to activate the mixture for fast-kill activity is carried out during manufacture and/or distribution to an end user.
A range of oral hygiene preparations may be envisaged which incorporate the anti-microbial compositions of the invention into conventional dental preparations such as mouthwashes, gargles and dentifrices as an anti-plaque agent and/or as a general antiseptic agent, for example in denture cleansing tablets or solutions. The oral hygiene compositions of the present invention may, if desired, contain one or more active ingredients conventionally used in the art. These include, for example, other anti-plaque agents such as bromochlorophene, triclosan, cetylpyridinium chloride and chlorhexidine salts; fluoride ion sources such as sodium fluoride, sodium monofluorophosphate and amine fluorides; anti-tartar agents such as zinc salts, preferably zinc citrate, and water soluble pyrophosphate salts, preferably alkali metal pyrophosphates; and agents which reduce tooth sensitivity including potassium salts such as potassium nitrate and potassium chloride and strontium salts such as strontium chloride and strontium acetate.
It will be appreciated that the compositions and methods of the invention are suitable for a whole host of anti-microbial applications in areas such as agriculture, horticulture, veterinary medicine, and aquaculture, such as trout farming.
The invention will be understood with reference to the following non-limiting Tests and Examples:
Comparative Test A
Two phases of an antimicrobial composition were prepared as follows: Phase A
Component Concentration (w/v%)
D-Glucose 45 to 55 Sodium Thiocyanate 0.42 to 0.52 Potassium Iodide 0.66 to 0.80
Phase B
Component Concentration
Lactoperoxidase 5500 Units/ml Glucose Oxidase 2250 Units/ml
Both phases were adjusted to between pH 5.5 and 6.5 with buffer solutions.
A test solution was prepared by mixing Phases A and
B together with water to concentrations of 0.9% and
0.05% respectively. An aliquot of the resulting solution was removed immediately and inoculated with
Pseudomonas aeruginosa.
The inoculated solution was incubated at room temperature. Samples were taken at regular intervals (viz at 0, 5, 10, 15, 30 and 60 minutes after mixing) and subjected to serial dilution and agar plating in known manner (normal aseptic technique being used throughout) to determine the numbers of any surviving organisms .
At each serial dilution point a parallel sample was taken, inoculated into a nutrient broth and incubated and then checked at an appropriate time for visual signs of growth. These parallel samples acted as so-called
"broth controls" to check that the inoculation had been performed correctly and to check whether viable organisms were present which might be missed by the serial dilution process. These controls show up as counts of "less than 10" (<10) on the agar plates.
The original mixture of Phases A and B and water was stored at room temperature for three months . Aliquots were taken at regular intervals (viz at 4 hours, 24 hours, 48 hours, 7 days, 13 days, 21 days, 27 days, 2 months and 3 months) and inoculated with Pseudomonas aeruginosa as described above to determine any change in the speed of kill .
Results are set out below in Table 1. In each case the "broth controls" are recorded as "+ve" or "-ve" above the corresponding plate counts .
Plate counts are given in "colony forming units per ml" (c.f.u. ml-1) . In each case "T" denotes the test solution and "C" a control (the buffer solution without Phases A and B above) .
Comparative Test B
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Staphylococcus aureus rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 2.
Comparative Test C
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Escherichia coli rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 3.
Comparative Test D
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Enterobacter cloacae rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 4.
Comparative Test E
The procedure of Comparative Test A above was repeated with the modification that the test and control solutions were inoculated with Corynebacterium xerosis rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 5.
Comparative Test F
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Candida albicans rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 6.
Comparative Test G
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Aspergillus niger rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 7. Comparative Test H
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Micrococcus luteus rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 8.
Comparative Test I
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Staphylococcus albus rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 9.
Comparative Test J
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Pityrosporum orale rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 10
Comparative Test K
The procedure of Comparative Test A above was repeated with the modifications that the test and control solutions were inoculated with Streptococcus mutans rather than Pseudomonas aeruginosa and that the storage times were varied. Results are set out in Table 11. Table 1
Pseudomonas aeruginosa c.f.u. ml -1x
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve +ve -ve -ve -ve 2.1xl06 l.lxlO6 5.8xl04 <10 <10 <10
C 1.7xl06
4 hours T +ve +ve -ve -ve -ve -ve 1.5xl05 <10 <10 <10 <10 <10
C 2.0xl06
24 T +ve -ve -ve -ve -ve -ve hours <10 <10 <10 <10 <10 <10
C 5.9xl05
48 T +ve -ve -ve -ve -ve -ve
10 hours <10 <10 <10 <10 <10 <10
C 2.3xl06
Table 1 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
7 days T +ve -ve -ve -ve -ve <10 <10 <10 <10 <10
C 1.3xl06 2.2xl06
13 days T +ve -ve -ve -ve -ve <10 <10 10 <10 <10
C 2.6xl06 2.0xl06
21 days T +ve -ve -ve -ve -ve <10 <10 <10 <10 <10
C 3.6xl06 3.2xl06
27 days T +ve -ve -ve -ve -ve <10 <10 <10 <10 <10
C 3.1xl06 3.0xl06
Table 1 continued
Table 2
Staphylococcus aureus c.f.u. ml x
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve +ve +ve
2.7xl06 2.7xl06 2.2xl06 2.2xl06 2.5xl05 <10
C 2.9xl06
4 hours T +ve +ve +ve -ve
2.6xl06 2.5xl05 2.4xl04 2.0X101 <10 <10
C 4.7xl06
24 T +ve +ve +ve +ve -ve hours 2.8xl06 2.4xl03 2.0X101 2.0X101 <10
C 2.8xl06
48 T +ve -ve -ve -ve -ve
10 hours 2.8xl04 <10 <10 <10 <10
C 4.1xl06
Table 2 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 ime
5 days T +ve +ve +ve -ve -ve 2.7xl06 3.2xl03 <10 <10 <10
C 3.2xl06
7 days T +ve +ve +ve -ve -ve 6.3xl05 5.0X101 l.OxlO1 7.0X101 <10
C 3.9xl06
14 days T +ve +ve -ve -ve -ve 1.2xl04 <10 <10 <10 <10
C 3.2xl06
28 days T +ve -ve -ve -ve -ve 6.6xl02 <10 <10 <10 <10
C 4.1xl06
Table 2 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 ime
2tf T +ve -ve -ve -ve -ve months 1.7xl04 <10 <10 <10 <10
C 2.6xl06
4 T +ve +ve +ve -ve -ve months 4.8xl05 <10 <10 <10 <10
C 4.4xl06 1.6xl06
6 T +ve +ve +ve +ve months 1.3xl06 3.4xl03 <10 <10
C 2.3xl06 2.0xl06
Table 3
Escherichia coli c . f . u . ml
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve +ve +ve -ve
5.6xl06 5.2xl06 4.8xl06 5.5xl06 8.4xl04 <10
C 4.2xl06 4.6xl06
4 hours T +ve -ve -ve -ve -ve -ve 2.7xl06 <10 <10 <10 <10 <10
C 2.6xl06 6.8xl06
24 T +ve -ve -ve -ve -ve -ve hours <10 <10 <10 <10 <10 <10
C 4.7xl06 4.5xl06
48 T +ve +ve -ve -ve -ve -ve
10 hours 3.3xl05 <10 <10 <10 <10 <10
C 4.9xl06 3.4xl06
Table 3 continued
Table 3 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
28 days T +ve -ve -ve -ve <10 <10 <10 <10
C 2.3xl06 3.0xl06
2 T -t-ve -ve -ve -ve months 3.7xl04 <10 <10 <10
C 4.9xl06 2.6xl06
3 T +ve -ve -ve -ve months <10 <10 <10 <10 c 3.2xl06 2.5xl06
Table 4
Enterobacter cloacae c.f.u. ml'
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve +ve -ve -ve
2.4xl06 3.5xl06 l.lxlO6 3.9xl06 <10 <10 c 5.7xl06
4 hours T +ve -ve -ve -ve -ve -ve 4.4xl05 <10 <10 <10 <10 <10 c 4.6xl06
24 T -ve -ve -ve -ve -ve -ve hours <10 <10 <10 <10 <10 <10 c 2.4xl06
48 T +ve +ve +ve -ve -ve -ve '
10 hours 2.7xl04 <10 <10 <10 <10 <10 c 2.5xl06
Table 4 continued
Table 4 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 ime
28 days T +ve -ve -ve -ve -ve l.OxlO1 <10 <10 <10 <10
C 5.8xl06 4.2xl06
2 T +ve -ve -ve -ve months <10 <10 <10
C 3.2xl06 3.4xl06
3 T +ve -ve -ve -ve months <10 <10 <10
C 6.7xl06 4.2xl06
Table 5
Corynebacterium xerosis c.f.u. ml -1
Sampling time (minutes)
Storage 0 5 10 15 30 60 ime
0 hours T +ve +ve +ve +ve +ve +ve 1.4xl06 9.3xl04 1.2xl04 5.1xl03 <10 <10
C 1.3xl06 l.lxlO6
4 hours T +ve +ve +ve +ve -ve -ve 3.4xl04 <10 <10 <10 <10 <10
C 8.7xl05 3.5xl05
24 T +ve -ve -ve -ve -ve -ve hours <10 <10 <10 <10 <10 <10
C 7.3xl05 7.5xl05
48 T +ve -ve -ve -ve -ve -ve
10 hours 2.7xl03 <10 <10 <10 <10 <10
C 6.3xl05 8.2xl05
Table 5 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
6 days T -t-ve -ve -ve -ve -ve <10 <10 <10 <10 <10 c 7.6xl05 9.4xl05
9 days T +ve -ve -ve -ve -ve <10 <10 <10 <10 <10 c 1.2xl05 9.5xl05
14 days T -i-ve -ve -ve -ve -ve <10 <10 <10 <10 <10 c 6.1xl06 4.2xl06
23 days T +ve -ve -ve -ve <10 <10 <10 <10 c 1.4xl06 1.8xl06
Table 5 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 ime
28 days T +ve -ve -ve -ve <10 <10 <10 <10
C 8.5xl05 9.3xl05
2 T +ve -ve -ve -ve months <10 <10 <10 <10
C 1.9xl06 8.2xl05
3 T +ve -ve -ve -ve months <10 <10 <10 <10
C 6.9xl05 6.1xl05
Table 6
Candida albicans c.f.u. ml —1■L
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve -t-ve -t-ve +ve +ve 2.8xl06 3.1xl06 3.2xl06 3.2xl06 2.4xl06 l.OxlO6
C 2.6xl06 2.3xl06
4 hours T +ve +ve H-ve +ve -i-ve -ve 2.1xl06 3.1xl06 1.2xl06 2.5xl05 <10 <10
C 2.5xl06 2.2xl06
24 T +ve +ve -ve -ve -ve -ve hours 2.0xl02 <10 <10 <10 <10 <10
C 8.2xl06 2.7xl06
48 T +ve -ve -ve -ve -ve -ve
10 hours 1.6xl06 <10 <10 <10 <10 <10
C 1.8xl06 2.2xl06
Table 6 continued
Table 6 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
2 T +ve -ve -ve -ve -ve months 6.0xl04 <10 <10 <10 <10
C 5.9xl06 6.6xl06
3 T +ve -ve -ve -ve -ve months 2.5xl05 <10 <10 <10 <10
C 1.8xl06 2.0xl06
Table 7
-1
Aspergillus niger c.f.u. ml •L
Sampling time (minutes)
Storage 0 5 10 15 30 60 75 ime
0 hours T -t-ve -t-ve +ve +ve +ve -t-ve 1.2xl06 5.0xl0β 1.6xl06 1.4xl06 l.OxlO6 1.2xl06
C 2.2xl07 1.3xl06
5 hours T +ve +ve +ve +ve +ve +ve 1.2xl06 1.2xl06 1.3xl06 5.0xl05 9.0xl05 4.0X101
C 1.3xl06 l.OxlO6
24 T -t-ve -t-ve +ve -ve -ve -ve hours 5.0xl06 l.OxlO1 <10 <10 <10 <10
C 3.7xl06 1.2xl06
4 days T -ve -ve -ve -ve -ve -ve
1.2xl05 <10 <10 <10 <10 <10 <10
C 2.4xl06 1.4xl06
Table 7 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 75 time
7 days T -ve -ve -ve -ve -ve -ve
4.0xl06 <10 <10 <10 <10 <10 <10
C 1.2xl06 9.0xl05
14 days T -ve -ve -ve -ve -ve l.lxlO6 <10 <10 <10 <10 <10
C 2.3xl06 1.9xl06
22 days T -ve -ve -ve -ve -ve l.OxlO5 <10 <10 <10 <10 <10
C 4.0xl06 2.9xl06
26 days T -ve -ve -ve -ve -ve l.OxlO6 <10 <10 <10 <10 <10
C 3.0xl06 2.6xl06
Table 7 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 75 ime
2 T -ve -ve -ve -ve -ve months 3.0xl06 <10 <10 <10 <10 <10
C 4.0xl06 6.0xl06
3 T -ve -ve -ve -ve -ve months 9.0xl05 <10 <10 <10 <10 <10
C 3.0xl06 2.0xl06
Table 8
Micrococcus luteus c.f.u. ml —1
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T -t-ve +ve -t-ve +ve +ve -t-ve 1.7xl05 1.8xl05 1.7xl05 1.3xl05 1.2xl05 2.2xl05 c 2.0xl05 1.4xl05
4 hours T +ve +ve H-ve H-ve -i-ve -t-ve 1.5xl05 8.0xl05 2.5xl04 7.5xl02 4.0X101 <10 c 1.2xl05 δ.7xl04
24 T -t-ve +ve -i-ve -ve -ve -ve hours 1.5xl05 1.4xl04 3.8xl02 <10 <10 <10 c 1.7xl05 1.7xl05
48 T -t-ve +ve +ve -ve -ve -ve
10 hours 4.7xl05 1.4xl02 <10 <10 <10 <10 c 4.7xl05 4.5xl05
Table 8 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
6 T +ve +ve +ve +ve -ve days 1.2xl05 3.3xl04 l.OxlO2 <10 <10
C 1.6xl05 1.3xl05
13 days T +ve +ve +ve -t-ve -i-ve l.δxlO5 <10 <10 <10 <10
C 2.2xl05 2.0x10s
20 days T +ve +ve -ve +ve -ve 2.5xl04 <10 <10 <10 <10
C 7.9xl04 8.4xl04
27 days T +ve +ve -ve -ve -ve 1.3xl05 <10 <10 <10 <10
C 1.8xl05 2.0x10s
Table 9
Staphylococcus albus c . f . u . ml ±
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T +ve +ve -t-ve +ve +ve -t-ve 2.3xlOβ l.lxlO6 2.0xl06 2.0xl06 1.6xl06 9.4xlOβ
C 1.9xl06 - 2.5xl06
4 hours T +ve -t-ve +ve +ve -ve -ve 2.0xl06 8.2xl0S 6.7xl04 1.5xl04 2.0X101 <10
C 2.4xl06 2.0xl06
24 T +ve +ve +ve +ve -ve -ve hours 2.0xl06 2.0x10s 1.8xl04 <10 <10 <10
C 2.3xl06 1.5xl06
48 T +ve -ve -ve -ve -ve -ve
10 hours 1.3xl06 1.5xl02 <10 <10 <10 <10
C 1.4xl06 1.6xl06
Table 9 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
6 T +ve +ve +ve -ve -ve days 2.1xl07 1.1x10s 8.7xl02 <10 <10
C 3.6xl06 l.δxlO6
13 days T +ve -ve -ve -ve -ve 2.8x10s 7.0X101 <10 <10 <10
C 1.9xl06 2.3xl06
20 days T +ve -ve -ve +ve -ve 2.7x10s <10 <10 <10 <10
C 2.3xl06 2.5xl06
27 days T +ve -ve -ve -ve -ve 1.8x10s <10 <10 <10 <10
C 9.6x10s l.lxlO6
Table 10
Pityrosporum ovale c . f . u . ml"
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T -t-ve +ve +ve
6.1xl04 4.8xl04 5.5xl04 3.7xl04 4.3xl04 9.0X101 c 4.7xl04 6.4xl04
4 hours T +ve -ve -ve -ve -ve -ve 5.1xl03 4.0X101 <10 <10 <10 <10 c 6.2xl04 2.δxl04
24 T +ve -ve -ve -ve -ve -ve hours 9.δxl03 <10 <10 <10 <10 <10 c 1.3xl04 1.2xl04
46 T -ve -ve -ve -ve -ve -ve
10 hours <10 <10 <10 <10 <10 <10 c 8.0xl04 5.4xl04
Table 10 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time δ T +ve -ve sampling -ve -ve days l.lxlO4 <10 interrupted <10 <10
C l.δxlO5 1.6x10s
15 days T -ve -ve -ve -ve -ve <10 <10 <10 <10 <10
C 2.1xl03 2.0xl03
22 days T +ve -ve -ve -ve -ve δ.OxlO1 <10 <10 <10 <10
C 2.9x10s 2.2x10s
29 days T -ve -ve -ve -ve
9.0X101 <10 <10 <10 <10
C 4.0x10s 3.9xl05
Table 11
Streptococcus mutans c.f.u. ml"
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
0 hours T -t-ve +ve -t-ve +ve -t-ve -t-ve 3.5x10s 4.7x10s 3.6x10s 3.4xlOS 3.4x10s 3.9xl04
C 3.δxl0s 2.0x10s
4 hours T -t-ve +ve -t-ve -ve -t-ve -ve 2.2xl05 1.1x10s 3.1xl04 1.3xl04 <10 <10
C 3.3xl05 2.1xl05
24 T +ve -t-ve +ve -i-ve -i-ve -ve hours 2.1x10s 7.4xl04 6.4xl02 δ.OxlO1 <10 <10
C 2.9xl05 2.1x10s
4δ T +ve +ve -ve -ve -ve -ve
10 hours l.OxlO6 <10 <10 <10 <10 <10
C 1.6xl06 l.OxlO6
Table 11 continued
Sampling time (minutes)
Storage 0 5 10 15 30 60 time
7 T -t-ve +ve -t-ve -t-ve -ve days 1.4x10s 2.0xl03 <10 <10 <10 c 1.7x10s 1.3x10s
13 days T -t-ve -ve -ve -ve -ve 3.9xl04 <10 <10 <10 <ια c 4.1xl05 3.1x10s
EFFECT OF pH
The following tests were carried out to assess the effect of pH on anti-microbial activity.
Test Procedure
Two phases of an antimicrobial composition were prepared as follows:
Phase A
Component Concentration (w/v % ] D-glucose 45 to 55 Sodium thiocyanate 0.42 to 0.52 Potassium iodide 0.66 to 0.80
Phase B
Component Concentration Lactoperoxidase 5,500 Units/ml Glucose Oxidase 2,250 Units/ml
Both phases were adjusted to between pH 5.5 and 6.5 with buffer solutions.
Test solutions were prepared by mixing Phases A and
B together with citrate phosphate buffer at pH 3, 4, 5, 6, 7, 8 to concentrations of 0.9% and 0.05% respectively. The test solutions were then stored at room temperature for 48 hours.
Aliquots of the stored test solutions were removed and inoculated with a single organism from the following organisms: E.coli, S.aureus, C.albicans, A.niger.
The inoculated solution was incubated at room temperature for 15 minutes serially diluted and agar plated to determine the numbers of any surviving organisms.
-1
Organism cfu ml ±
E.coli S.aureus C.albicans A.niger
Initial 8.2xl05 2.4xl06 1.2xl0β l.OxlO5
Inoculum count pH 3 <10 <10 1.9xl06 <10 pH 4 <10 <10 <10 <10 pH 5 <10 5.0xl03 <10 <10 pH 6 <10 5.0xl05 <10 <10 pH 7 1.2xl02 6.4xl05 <10 3-OxlO1 pH 8 <10 2.1xl06 1.7xl05 1.7xl03
The above results demonstrate that pH can be chosen so as to kill a particular micro-organism selectively. For example, at pH 8 only E.coli is killed. Broad spectrum anti-microbial activity is obtained when the pH is around 4 in the above tests .
Example 1
Glycol paint for athlete's foot or acne
A biphasic glycol paint is prepared to the following composition:
Component A Amount/5Oα
Propylene glycol 30g
D-Glucose ig
Sodium thiocyanate 8.4mg
Potassium iodide 13.2mg
Water to 50g
Component B Amount/5Oα
Glucose oxidase (available under the Trade Designation "Glucox P200") 112U 15ppm)
Lactoperoxidase 275U (lOppm)
Water to 50g
Using a suitably designed dispenser 1 part of Component A is combined with 1 part of Component B and allowed to stand for the required activation time. After this period the mixed components can be applied to control two strains of inter alia Staphylococcus aureus and also Propionibacter acnes, Candida albicans, Trichoderma rubrum, Trichoderma mentagrophytes and Trichoderma interdigitale. Example 2
Roll-on Deodorant
A biphasic roll-on deodorant is prepared to the following composition:
Component A Amount/8Og
Tetrasodium EDTA 0.125g
Mixture of stearates (available under the Trade Designation
"Cithrol GMS A/S") 3.75g Ethoxylated fatty alcohol (available under the Trade Designation "Cromul EM 0685") 3.125g
Light liquid paraffin 3.75g
D-Glucose 0.625g
Sodium thiocyanate 5.25mg Potassium iodide 8.25mg
Water to 80g
Component B Amount/2Oq
Glucose oxidase (available under the Trade Designation "Glucox P200") 260U
(37.5ppm)
Lactoperoxidase 687.5U (25ppm)
Water to 20g
Using a suitably designed dispenser, 4 parts of Component A are combined with 1 part of Component B in a mixing chamber and allowed to stand for the required activation time. After this period the mixed components can be applied to provide the necessary killing activity against inter alia two strains of Staphylococcus aureus. Example 3
Anti-dandruff shampoo
A biphasic antibacterial anti-dandruff shampoo is prepared to the following composition:
Component A Amount/8Oqms
Sodium laureth-2-sulphate (23% soln) 68.75g
Zinc sulphate 0.125g Mixture of diethanolamides (available under the Trade Designation "Empilan CDE") 6.25g Stearic acid toilet 1.25g Mixture of mono and distearates (available under the Trade Designation "Empilan EGMS") 3.75g
D-Glucose 0.625g
Sodium thiocyanate 5.25mg Potassium iodide 8.25mg
Water to lOOg
Component B Amount/2Oqms
Glucose oxidase (available under the Trade Designation "Glucox P200") 280U (37.5ppm)
Lactoperoxidase 687.5U
(25ppm) Water to 20g
Using a suitably designed dispenser 4 parts of Component A are combined with 1 part of Component B and allowed to stand for the required activation time. After this period the mixed components can be applied to achieve the desired killing activity against inter alia S. aureus and Pityrosporum ovale. CONCENTRATED FORMULATION
Example Sterilising Concentrate for Dilution
Concentration
Glucose 45% w/v
Sodium Thiocyanate 0.42% w/v
Potassium Iodide 0.66% w/v
Potassium Dihydrogen Phosphate 0.62% w/v
Sodium Hydroxide 0.02% w/v
Glucose Oxidase 5600 U
Lactoperoxidase 13750 U
Water q.s to 100% volume
In the above concentrated formulation the components are pre-activated by incubation during manufacture and distribution. The concentration is then diluted 1 part in 100 parts of water to yield a steriling solution with fast-kill activity.
The concentrated formulation is advantageous because the weight of product is greatly reduced compared to the liquid solution, making the concentrated product relatively cheap to distribute. The concentrate formulation is also convenient for the end user because it is easier to transport and takes up less storage space than the equivalent liquid solution.
Example 4
Sterilant solution (eg for contact lenses)
A biphasic sterilant solution is prepared to the following composition:
Component A Amount/5Oq
D-Glucose ig Sodium thiocyante 8.4mg Potassium iodide 13.2mg Water to 50g
Component B Amount/5Oq
Glucose oxidase (available under the Trade Designation "Glucox P200") 112U (15ppm)
Lactoperoxidase 275U (lOppm)
Water to 50g
Using a suitably designed dispenser 1 part of Component A is combined with 1 part of Component B and allowed to stand for the required activation time. After this period the mixed components can be applied to give effective control of Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Streptococcus mutans, Enterobacter cloacae and Candida albicans.
An example of packaging suitable for use in the method of the present invention will now be described, by way of example only, with reference to the accompanying drawings, in which: Figure 1 shows a side section view of a packaged chemical composition according to the present invention, along the line I-I of Figure 2; and
Figure 2 shows a plan section view of the packaged chemical composition of Figure 1 along the line II- II of Figure 1.
The packaged chemical composition, generally indicated as 1, comprises a first reservoir 2 and a second reservoir 3. The reservoirs are of approximately equal size and are generally tubular in shape. The reservoir walls 4,5 are made from resilient polyethylene but it will be appreciated that other resilient materials, such as polyvinylchloride (PVC) or polyethyleneterephthalate (PET) may also be used if desired. The walls are strong enough to avoid the risk of breakage but flexible enough to permit "squeezing" of the contents in use.
One of the reservoirs, 2, houses Component A from Example 1 above and the other reservoir, 3, houses Component B therefrom. The reservoirs 2,3 are substantially sealed so that no leakage of contents can occur from one to the other. For convenience they are welded together at one point by a polythene web 6 which is continuous with the reservoir walls 4,5. The walls of the reservoirs are independently deformable such that it is possible to deform one reservoir, for example by "squeezing", without deforming the other, if desired.
The lower end of the reservoirs provide a base 7 to allow the packaging to be rested in an upright position. The upper ends of the reservoirs 2,3 are constricted to form a neck 8 which is blocked by a neck-piece 9 made of stiff non-resilient polyethylene. The neck 8 and neck¬ piece 9 support a bulbous incubation chamber 10. The incubation chamber 10 is constricted at its upper end to provide a second neck 11 which is threaded in the manner of a screw-top bottle neck to connect with a screw-cap 12 which may be used to close off the packaging when not in use.
Polythene tubes 13,14 extend substantially from the bases of the two reservoirs 2,3 respectively, through holes in the neck-piece 9, with which they form an interference fit, to the base of the incubation chamber 10. The tubes 13,14 are narrow enough to prevent significant leakage of the contents of the reservoirs 2,3 into the incubation chamber 10 during normal storage. Such leakage as may occur is contained by the cap 12. However, when the cap 12 is removed and one or both of the reservoir walls is deformed, for example by "squeezing", a portion of the reservoir contents is forced up the tube 13 or 14 by the pressure created and into the incubation chamber 10.
In use, controlled mixing of the reservoir contents (Components A and B of Example 1 above) is achieved by squeezing each of the reservoirs in turn and/or simultaneously by roughly equal amounts to introduce equal quantities of the reservoir solutions into the incubation chamber 10. Indicia 15 are provided on the walls of the incubation chamber 10 to assist in measuring the quanitities to be mixed. The walls of the incubation chamber are made from transport/translucent polyethylene to assist in the measuring process but this is, not essential and it will be appreciated that opaque plastics materials may be used if desired. The cap 12 may then be replaced and the apparatus 1 may be shaken gently to complete the mixing process. The resulting mixture is left to incubate for the desired period, typically from 5 to 10 minutes.
After incubation the cap 12 is removed and the incubated anti-microbial mixture is used in the desired manner, by application to the feet or other areas affected by so-called "athlete's foot".
It will be appreciated that the packaging could house any of the other Examples given above and/or numerous variants thereof. Where the components are not mixed in equal proportions (eg Examples 2 and 3 above) the reservoirs may be made of correspondingly unequal size and corresponding modifications may be made to the other parts of the apparatus as appropriate. Thus, if four parts of component A are needed to each part of component B, then the reservoir housing component A may be squeezed four times as often as the reservoir housing component B (as in Example 3 above) , until the desired quantity of mixture has been generated in the incubation chamber 10. Alternatively or additionally, the indicia 15 may be used to measure the required proportions.
Instructions for mixing the components in the appropriate proportions will normally be supplied with the apparatus, preferably by printing onto the packaging itself.

Claims

1 A method of killing microorganisms by mixing effective amounts of D-glucose and glucose oxidase, incubating the resulting mixture at a temperature of from -10 to 50°C and at a pH of from 1 to 8 for a period of at least about 30 minutes and then applying the incubated mixture to the microorganisms to be killed.
2 A method as claimed in Claim 1 wherein the resulting mixture is incubated for 12 to 48 hours .
3 A method as claimed in any preceding claim wherein the concentration of glucose oxidase in the resulting mixture is at least 25 U/kg.
4 A method as claimed in any preceding claim wherein the resulting mixture comprises iodide anions and/or thiocyanate anions.
5 A method as claimed in any preceding claim wherein the resulting mixture comprises both iodide anions and thiocyanate anions .
6 A method as claimed in Claim 5 wherein the weight ratio of iodide anions to thiocyanate anions is from
0.1:1 to 50:1.
7 A method as claimed in Claim 6 wherein the combined anion weight concentration is at least 5 mg/kg.
8 A method as claimed in any preceding claim wherein the resulting mixture further comprises a peroxidase enzyme.
9 A method as claimed in Claim 8 wherein the peroxidase enzyme is lactoperoxidase. 10 A method as claimed in any preceding claim wherein the incubated mixture is provided as a concentrate for dilution to produce a solution for killing microorganisms.
11 A method as claimed in any of Claims 1 to 9 wherein the components are provided as a concentrated biphasic composition in packaged and substantially non-reacting form.
12 Apparatus in the form of a packaged chemical composition for use in the method defined in Claim 1 said apparatus comprising:
a) a first reservoir comprising a source of D-glucose; b) a second reservoir comprising a source of glucose oxidase; c) an incubation chamber connected to said first and second reservoirs; and d) means for introducing controlled quantities of said
D-glucose and glucose oxidase into said incubation chamber to prepare and incubate a biocidal mixture of glucose and glucose oxidase ready for use.
EP95928872A 1994-03-26 1995-03-18 Method of killing microorganisms Withdrawn EP0752815A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9406075A GB9406075D0 (en) 1994-03-26 1994-03-26 Method of killing microorganisms
GB9406075 1994-03-26
PCT/EP1995/001037 WO1995026137A1 (en) 1994-03-26 1995-03-18 Method of killing microorganisms

Publications (1)

Publication Number Publication Date
EP0752815A1 true EP0752815A1 (en) 1997-01-15

Family

ID=10752601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95928872A Withdrawn EP0752815A1 (en) 1994-03-26 1995-03-18 Method of killing microorganisms

Country Status (8)

Country Link
EP (1) EP0752815A1 (en)
AU (1) AU697046B2 (en)
CA (1) CA2186531A1 (en)
GB (1) GB9406075D0 (en)
IL (1) IL113070A (en)
NZ (1) NZ283139A (en)
WO (1) WO1995026137A1 (en)
ZA (1) ZA952363B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708641D0 (en) * 1997-04-29 1997-06-18 Knoll Ag Enzyme concentrate
US5972355A (en) * 1997-09-30 1999-10-26 E-L Management Corp. Stable compositions containing biologically active components
CA2309500C (en) * 1997-11-05 2012-04-17 Koppert B.V. Pesticide against plant-pathogenic micro-organisms
GB0100643D0 (en) 2001-01-10 2001-02-21 Basf Ag Liquid antimicrobial compositions
GB0328156D0 (en) 2003-12-04 2004-01-07 Basf Ag Antimicrobial compositions comprising polymeric stabilizers
US20060289354A1 (en) * 2005-06-15 2006-12-28 Buckman Laboratories International, Inc. Method and composition to control the growth of microorganisms in aqueous systems and on substrates
WO2009116944A1 (en) * 2008-03-20 2009-09-24 Krister Tano Use of a substance for manufacturing of a medicament for treatment of common cold
EP2987408A1 (en) * 2014-08-20 2016-02-24 National University of Ireland, Galway Iodophor composition with improved stability in the presence of organic material
CN113412901A (en) * 2021-07-13 2021-09-21 广州沃邦生物科技有限公司 Coco ferment pseudomonas antibacterial composition and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9526137A1 *

Also Published As

Publication number Publication date
NZ283139A (en) 1998-09-24
WO1995026137A1 (en) 1995-10-05
CA2186531A1 (en) 1995-10-05
IL113070A (en) 1999-10-28
AU697046B2 (en) 1998-09-24
ZA952363B (en) 1995-09-26
AU2110395A (en) 1995-10-17
IL113070A0 (en) 1995-06-29
GB9406075D0 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
EP0514417B1 (en) Anti-microbial compositions
EP3125952B1 (en) Stable compositions of uncomplexed iodine and methods of use
AU697046B2 (en) Method of killing microorganisms
EP1094710B1 (en) Sporicidal composition
EP1349457B1 (en) Liquid antimicrobial compositions
CN102846489B (en) Polyhexamethyleneguanidine hydrochloride iodine medicine bath liquid and preparation method thereof
AU2002217319A1 (en) Liquid antimicrobial compositions
KR0179236B1 (en) Humidifier Detergent Composition Using Natural Extracts
GB2120550A (en) Improvements in or relating to iodophors
CN107306992A (en) A kind of salicylic acid-iodine powder disinfectant and preparation method thereof
AU2020401747A1 (en) Antimicrobial composition
IL293760A (en) Antimicrobial composition
JPH09315927A (en) Cosmetic
CN102349510A (en) Composite disinfectant for livestock and poultry and using method
JP2001010913A (en) Silver ion water containing minute quantity of metal ion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19971007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991217